Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral amenamevir for acyclovir-resistant epithelial herpetic keratitis (pilot study)
jRCTs061190001Completed
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of Amenamevir in herpetic keratitis. Primary endpoint: Disappearance of herpetic epithelial lesion at 14 days. Started May 2019; status: completed.
02
Drugs
Amenamevir
03
Conditions
herpetic keratitis
Beyond the preview
Go deeper on jRCTs061190001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061190001.